Valeant Pharmaceuticals (VRX.TO) Buy, Sell or…

Valeant Pharmaceuticals (VRX.TO)

0.00

-0.00 (0.00%)

39 watching

TOP PICK

Terrific yield and an outstandingly good balance sheet. As a medical process that works, a slow release kind of stuff. Stock is very cheap. Kind of stock where only good things can happen. Thinks the yield is safe.

DON'T BUY

New management team seems to have done a pretty good job in terms of running the operation. Made a big acquisition, which always makes investors nervous. 15.25% yield could possibly be cut. This stock is too difficult to work out with all the moving parts.

DON'T BUY

Eugene Melnyk's challenge of the Board of Directors was withdrawn and very positive for the stock. Jury is out on whether they have sufficient drugs in the pipeline to turn it into a growth company. Would prefer others in generic drugs such as Teva (TEVA-Q).

COMMENT

Hasn't been in his portfolio for several years. Plagued with bad news. Just needs some good news somewhere. Model price is $21.27, a positive 100% differential. He is seeing a little bit of traction in this group.

DON'T BUY

Has many internal difficulties. A company that is very hard for him to understand what is going on.

DON'T BUY

Has had a very chequered history. Base business is quite attractive. With all the controversy surrounding it she would wait until things settle down.

DON'T BUY

Doesn't like their old strategy of trying to make “hard to manufacture” generics. New management has a completely viable strategy focusing on high-value add central nervous system drugs. However, they have never shown any skill set and it's a very competitive market.

DON'T BUY

Showing declining revenues. Volatile sector – been a disaster in past years. This stock is ahead in this sector but will face generics. Revenue profile is declining. Could add to position as a value play. Doesn’t like the sector.

DON'T BUY

Having fights about who’s going to be on the board and who’s going to run the show. Doesn’t like companies with this kind of dissension. 12.5% dividend and the market is saying that is unsustainable.

DON'T BUY

In a proxy fight with the founder trying to get back the company. Not a bad company but in a bad environment with the FDA right now.

SELL

(Market Call Minute.) Can't go up from here. Just had another change in management and there are no products on the horizon.

DON'T BUY

The former chairman is suing present chairman. Under investigation by the SCC. Not a stock you want to be in.

DON'T BUY

Earned $1.24 per share but paid $1.53 per share. Companies cannot sustain a dividend far ahead of their earnings for very long. Have had a number of problems over the last year. He wonders where the stability is going to come from.

COMMENT

This stock has lots of value, however bad news just keeps coming in. Model price is $24.36 but there are constant downward revisions in earnings. A lot of fat there. If you have tight stops, stick out your hand. If it broke down to $10.36, it will drop to $8.50.

DON'T BUY

The pharma sector has had a rotten time, declining earnings. This company will have worst earnings than last year. Would avoid the stock (Not value investors, don’t try to pick bottoms), in a declining environment this will perform poorly.

Showing 271 to 285 of 714 entries

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Keith Richards

ValueTrend Wealth Management

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Valeant Pharmaceuticals (VRX.TO)